In the wake of the increase in Current Liabilities in the third quarter 2022, Quick Ratio fell to 0.02 above Cen Biotech Inc average.

Within Major Pharmaceutical Preparations industry 636 other companies have achieved higher Quick Ratio than Cen Biotech Inc in third quarter 2022. While Quick Ratio total ranking in the third quarter 2022 has deteriorated compared to the prior quarter from 5178 to 6011.

Explain Quick Ratio?
How much Cash & cash equivalents CENB�s has?
What are CENB�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CENB Quick Ratio	(Sep 30 2022) Q3	(Dec 31 2021) Q2	(Sep 30 2021) Q1	(Jun 30 2021) Q4	(Mar 31 2021) Q3
Y / Y Current Liabilities Change	-34.78 %	-81.18 %	-68.6 %	-68.05 %	-52.95 %
Y / Y Cash & cash equivalent Change	18893.72 %	10025.79 %	84743.25 %	28.44 %	-49.48 %
Quick Ratio MRQ	0.02	0.07	0.02	0	0
CENB's Total Ranking	# 6011	# 5178	#	#	#
Seq. Current Liabilities Change	255.16 %	-74.55 %	1.94 %	-29.23 %	2.47 %
Seq. Cash & cash equivalent Change	-23.32 %	-9.64 %	1872.37 %	1289.74 %	-59.12 %

Quick Ratio third quarter 2022 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 637
Healthcare Sector	# 1285
Overall Market	# 6011

Quick Ratio Statistics
High	Average	Low
0.07	0.01	0
(Dec 31 2021)		(Sep 30 2020)

Financial Statements
Cen Biotech Inc's Current Liabilities	$ 10 Millions	Visit CENB's Balance sheet
Cen Biotech Inc's Cash & cash equivalent	$ 0 Millions	Visit CENB's Balance sheet
Source of CENB's Sales		Visit CENB's Sales by Geography

Cumulative Cen Biotech Inc's Quick Ratio

CENB's Quick Ratio for the trailling 12 Months

CENB Quick Ratio	(Sep 30 2022) 12 Months	(Dec 31 2021) 12 Months	(Sep 30 2021) 12 Months	(Jun 30 2021) 12 Months	(Mar 31 2021) 12 Months
Y / Y Current Liabilities TTM Growth	-65.09 %	-65.68 %	-60.8 %	-40.43 %	-18.13 %
Y / Y Cash & cash equivalent TTM Growth	4873.6 %	3347.18 %	1524.62 %	-3.9 %	-47.97 %
Quick Ratio TTM	0.02	0.01	0	0	0
Total Ranking TTM	# 4606	# 5442	# 5509	# 5859	# 4789
Seq. Current Liabilities TTM Growth	-13.31 %	-23.27 %	-31.64 %	-23.23 %	-14.78 %
Seq. Cash & cash equivalent TTM Growth	35.2 %	84.15 %	1549.73 %	21.09 %	-6.29 %

Quick ratio ranking by company, industry and sector >> Back to CENB Financial Strength Comparisons >> Go to Compare CENB Quick Ratio to its Competitors

On the trailing twelve months basis CENB Cash & cash equivalent more than doubled by 18893.72 % in Q3 2022 year on year, while Current Liabilities more than doubled to $10 millions, this led to increase in in Cen Biotech Inc's Quick Ratio to 0.02, above CENB average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 578 other companies have achieved higher Quick Ratio than Cen Biotech Inc. While Quick Ratio overall ranking has improved so far to 4741, from total ranking during the twelve months ending fourth quarter 2021 at 4746.

Explain Quick Ratio?
How much Cash & cash equivalents CENB�s has?
What are CENB�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 579
Healthcare Sector	# 1166
Within the Market	# 6011

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.02	0.01	0
(Jun 30 2022)		(Sep 30 2020)

Companies with similar Quick Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2022 MRQ Cash & cash equivalent	Sep 30 2022 MRQ Current Liabilities
Cytodyn inc	0.04	$ 4.676 Millions	$ 122.319 Millions
Emmaus Life Sciences Inc	0.03	$ 1.179 Millions	$ 41.523 Millions
Viveon Health Acquisition Corp	0.03	$ 0.286 Millions	$ 10.607 Millions
Rebus Holdings Inc	0.02	$ 0.134 Millions	$ 5.711 Millions
Statera Biopharma Inc fka Cytocom Inc	0.02	$ 0.506 Millions	$ 22.231 Millions
Bespoke Extracts Inc	0.02	$ 0.011 Millions	$ 0.519 Millions
Aeon Biopharma inc	0.02	$ 0.028 Millions	$ 1.348 Millions
Cell Source Inc	0.02	$ 0.066 Millions	$ 3.549 Millions
Q Biomed inc	0.02	$ 0.138 Millions	$ 7.732 Millions
Oncotelic Therapeutics Inc	0.02	$ 0.254 Millions	$ 16.211 Millions
Cen Biotech Inc	0.02	$ 0.148 Millions	$ 9.828 Millions
Lifecore Biomedical Inc	0.01	$ 2.540 Millions	$ 172.221 Millions
Intellipharmaceutics International Inc	0.01	$ 0.080 Millions	$ 5.893 Millions
Novaccess Global Inc	0.01	$ 0.064 Millions	$ 4.778 Millions
Actavia Life Sciences Inc	0.01	$ 0.039 Millions	$ 3.012 Millions
Nanomix Corp	0.01	$ 0.050 Millions	$ 3.897 Millions
Innovation1 Biotech Inc	0.01	$ 0.366 Millions	$ 29.812 Millions
Bioadaptives Inc	0.01	$ 0.018 Millions	$ 1.626 Millions
Provectus Biopharmaceuticals Inc	0.01	$ 0.067 Millions	$ 8.824 Millions
Sangui Biotech International Inc	0.01	$ 0.007 Millions	$ 0.911 Millions
Regen Biopharma Inc	0.01	$ 0.051 Millions	$ 7.328 Millions
Propanc Biopharma Inc	0.01	$ 0.019 Millions	$ 2.822 Millions
Adhera Therapeutics Inc	0.01	$ 0.133 Millions	$ 22.063 Millions
Globestar Therapeutics Corporation	0.01	$ 0.006 Millions	$ 1.205 Millions
Kaya Holdings Inc	0.00	$ 0.040 Millions	$ 12.878 Millions
American Bio Medica Corporation	0.00	$ 0.010 Millions	$ 3.192 Millions

Date modified: 2026-08-30T04:42:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.